QT Prolongation Risk in Antihistamine Therapy
Guideline-Based Recommendations
- The American College of Gastroenterology recommends choosing diphenhydramine over hydroxyzine in patients with cardiovascular risk factors, as diphenhydramine is notably absent from guideline lists of QT-prolonging medications that require routine cardiac monitoring 1
- The European Society of Cardiology guidelines suggest avoiding concomitant QT-prolonging medications when hydroxyzine must be used despite risk factors, and monitoring QTc after dose changes 2
- The European Society of Cardiology also recommends particular caution with hydroxyzine in elderly patients 2
Clinical Decision Making
- For patients requiring antihistamine therapy with cardiovascular risk factors, the European Society of Cardiology suggests choosing diphenhydramine over hydroxyzine, or selecting alternative antihistamines (fexofenadine, desloratadine) 1
- If hydroxyzine must be used despite risk factors, the European Society of Cardiology recommends avoiding concomitant QT-prolonging medications 2
QT Prolongation with Antihistamines
Introduction to QT Prolongation Risk
- The American Academy of Pediatrics recommends that hydroxyzine is explicitly listed in pediatric guidelines as a QT-prolonging antihistamine alongside loratadine 3, 4
- The British Journal of Dermatology guidelines suggest considering alternative antihistamines (fexofenadine, desloratadine) in patients with multiple risk factors 5, 6
Clinical Management Recommendations
- Obtain baseline ECG before initiating hydroxyzine therapy in any patient with cardiovascular risk factors, and monitor QTc at baseline and after dose adjustments, with particular attention to QTc >500 ms or increases >60 ms from baseline 7
- Correct electrolyte abnormalities (potassium <4.5 mEq/L, hypomagnesemia) before starting hydroxyzine therapy 7